Influenza vaccines and immunopathology

Expert Review of Vaccines

Volumn 11, Issue 8, 2012, Pages 873-875

  Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

immunopathology; influenza; narcolepsy; vaccination

Indexed keywords

ANTIGEN; DNA VACCINE; HLA DQB1 ANTIGEN; INFLUENZA VACCINE; NUCLEOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL INFECTION; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CROSS REACTION; DISEASE SEVERITY; DRUG SAFETY; HUMAN; IMMUNOPATHOLOGY; INFLUENZA; INFLUENZA VACCINATION; NARCOLEPSY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIROTHERAPY; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CROSS PROTECTION; HLA-DQ BETA-CHAINS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NARCOLEPSY; PANDEMICS;

EID: 84866679821     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.65     Document Type: Review

References (26)

1. Shanks GD, Brundage JF. Pathogenic responses among young adults during the 1918. influenza pandemic. Emerging Infect. Dis. 18(2), 201-207 (2012)
2. Brundage JF, Shanks GD. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerging Infect. Dis. 14(8), 1193-1199 (2008).
3. He XS, Holmes TH, Mahmood K et al. Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J. Infect. Dis. 197(6), 803-811 (2008).
4. Bodewes R, Fraaij PL, Geelhoed-Mieras MM et al. Annual vaccination against influenza virus hampers development of virus-specific CD8+ T cell immunity in children. J. Virol. 85(22), 11995-12000 (2011).
5. McMichael AJ, Gotch FM, Dongworth DW, Clark A, Potter CW. Declining T-cell immunity to influenza, 1977-82. Lancet 2(8353), 762-764 (1983).
6. Mathews JD, McBryde ES, McVernon J, Pallaghy PK, McCaw JM. Prior immunity helps to explain wave-like behaviour of pandemic influenza in 1918-9. BMC Infect. Dis. 10, 128 (2010).
7. Hardelid P, Andrews NJ, Hoschler K et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. Health Technol. Assess. 14(55), 115-192 (2010).
8. Couch RB, Atmar RL, Franco LM et al. Prior infections with seasonal influenza A/H1N1 virus reduced the illness severity and epidemic intensity of pandemic H1N1 influenza in healthy adults. Clin. Infect. Dis. 54(3), 311-317 (2012).
9. Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 15(8), 865-868 (1997).
10. Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HG, Lunn DP. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 24(8), 1180-1190 (2006).
11. Laddy DJ, Yan J, Khan AS et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J. Virol. 83(9), 4624-4630 (2009).
12. Bodewes R, Kreijtz JH, Baas C et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS ONE 4(5), e5538 (2009).
13. Bodewes R, Kreijtz JH, Geelhoed-Mieras MM et al. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J. Virol. 85(6), 2695-2702 (2011).
14. Moskophidis D, Kioussis D. Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J. Exp. Med. 188(2), 223-232 (1998).
15. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J. Gen. Virol. 83(Pt 8), 1851-1859 (2002).
16. Lillie PJ, Berthoud TK, Powell TJ et al. A preliminary assessment of the efficacy of a T cell-based influenza vaccine, MVANP+ M1, in humans. Clin. Infect. Dis. 55(1), 19-25 (2012).
17. Wilkinson TM, Li CK, Chui CS et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18(2), 274-280 (2012).
18. Atsmon J, Kate-Ilovitz E, Shaikevich D et al. Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine. J. Clin. Immunol. 32(3), 595-603 (2012).
19. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7(3), e33723 (2012).
20. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 343, d5956 (2011).
21. Han F. Sleepiness that cannot be overcomenarcolepsy and cataplexy. Respirology doi:10.1111/j.1440-1843.2012.02178.x (2012) (Epub ahead of print).
22. Viorritto EN, Kureshi SA, Owens JA. Narcolepsy in the pediatric population. Curr. Neurol. Neurosci. Rep. 12(2), 175-181 (2012).
23. Walker WT, de Whalley P, Andrews N et al. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. Clin. Infect. Dis. 54(5), 661-669 (2012).
24. Lambe T, Spencer AJ, Mullarkey CE et al. T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic h1n1 influenza vaccine, and response to revaccination with seasonal trivalentinactivated influenza vaccine. Pediatr. Infect. Dis. J. 31(6), e86-e91 (2012).
25. Wieczorek S, Gencik M, Rujescu D et al. TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 61(6), 437-442 (2003).
26. Tanaka S, Honda Y, Honda M. MX2 gene expression tends to be downregulated in subjects with HLA-DQB1*0602. Sleep 31(5), 749-751 (2008).